A phase II study of neoadjuvant capecitabine, oxaliplatin, and irinotecan (XELOXIRI) in patients with locally advanced rectal cancer
Abstract Purpose Addition of perioperative multi‐agent chemotherapy to the treatment strategy for locally advanced rectal cancer (LARC) may be a promising option. We conducted a phase II study to evaluate the safety and efficacy of capecitabine combined with oxaliplatin and irinotecan (XELOXIRI) as...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-01-01
|
| Series: | Annals of Gastroenterological Surgery |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/ags3.12600 |
| _version_ | 1797956297738420224 |
|---|---|
| author | Chu Matsuda Toshihiro Kudo Yoshihiro Morimoto Yoshinori Kagawa Mitsuyoshi Tei Yoshihito Ide Norikatsu Miyoshi Hidekazu Takahashi Mamoru Uemura Ichiro Takemasa Taroh Satoh Tsunekazu Mizushima Kohei Murata Yuichiro Doki Hidetoshi Eguchi Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group (MSCSGO) |
| author_facet | Chu Matsuda Toshihiro Kudo Yoshihiro Morimoto Yoshinori Kagawa Mitsuyoshi Tei Yoshihito Ide Norikatsu Miyoshi Hidekazu Takahashi Mamoru Uemura Ichiro Takemasa Taroh Satoh Tsunekazu Mizushima Kohei Murata Yuichiro Doki Hidetoshi Eguchi Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group (MSCSGO) |
| author_sort | Chu Matsuda |
| collection | DOAJ |
| description | Abstract Purpose Addition of perioperative multi‐agent chemotherapy to the treatment strategy for locally advanced rectal cancer (LARC) may be a promising option. We conducted a phase II study to evaluate the safety and efficacy of capecitabine combined with oxaliplatin and irinotecan (XELOXIRI) as triplet neoadjuvant chemotherapy in patients with LARC. Methods Patients received neoadjuvant irinotecan and oxaliplatin and capecitabine and then underwent total mesorectal excision. The primary study endpoint was the pathological complete response (pCR) rate. Results Between June 2013 and December 2016, 55 patients were enrolled in the study. Forty‐two (77.8%) of 54 completed the study protocol. The pCR rate was 7.7% (95% CI 3.0% to 18.2%). The 3‐year local recurrence rate was 3.9%, the 3‐year disease‐free survival (DFS) rate was 77.3, and the 3‐year overall survival rate was 96.0%. Conclusion XELOXIRI neoadjuvant chemotherapy appears to be feasible and efficacious for patients with LARC. Although neoadjuvant XELOXIRI alone did not yield our expected pCR rate, the local recurrence rate, 3‐year DFS, and measures of safety met current standards. |
| first_indexed | 2024-04-10T23:46:46Z |
| format | Article |
| id | doaj.art-3eb8581c6edc4b6cb42324eb3f36b42d |
| institution | Directory Open Access Journal |
| issn | 2475-0328 |
| language | English |
| last_indexed | 2024-04-10T23:46:46Z |
| publishDate | 2023-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Annals of Gastroenterological Surgery |
| spelling | doaj.art-3eb8581c6edc4b6cb42324eb3f36b42d2023-01-11T02:40:41ZengWileyAnnals of Gastroenterological Surgery2475-03282023-01-0171819010.1002/ags3.12600A phase II study of neoadjuvant capecitabine, oxaliplatin, and irinotecan (XELOXIRI) in patients with locally advanced rectal cancerChu Matsuda0Toshihiro Kudo1Yoshihiro Morimoto2Yoshinori Kagawa3Mitsuyoshi Tei4Yoshihito Ide5Norikatsu Miyoshi6Hidekazu Takahashi7Mamoru Uemura8Ichiro Takemasa9Taroh Satoh10Tsunekazu Mizushima11Kohei Murata12Yuichiro Doki13Hidetoshi Eguchi14Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group (MSCSGO)Department of Gastroenterological Surgery, Graduate School of Medicine Osaka University Osaka JapanDepartment of Gastroenterological Surgery, Graduate School of Medicine Osaka University Osaka JapanDepartment of Gastroenterological Surgery, Graduate School of Medicine Osaka University Osaka JapanDepartment of Gastroenterological Surgery Kansai Rosai Hospital Amagasaki JapanDepartment of Surgery Osaka Rosai Hospital Osaka JapanDepartment of Surgery Yao Municipal Hospital Osaka JapanDepartment of Gastroenterological Surgery, Graduate School of Medicine Osaka University Osaka JapanDepartment of Gastroenterological Surgery, Graduate School of Medicine Osaka University Osaka JapanDepartment of Gastroenterological Surgery, Graduate School of Medicine Osaka University Osaka JapanDepartment of Surgery, Surgical Oncology and Science Sapporo Medical University Sapporo JapanDepartment of Gastroenterological Surgery, Graduate School of Medicine Osaka University Osaka JapanDepartment of Gastroenterological Surgery, Graduate School of Medicine Osaka University Osaka JapanDepartment of Gastroenterological Surgery Kansai Rosai Hospital Amagasaki JapanDepartment of Gastroenterological Surgery, Graduate School of Medicine Osaka University Osaka JapanDepartment of Gastroenterological Surgery, Graduate School of Medicine Osaka University Osaka JapanAbstract Purpose Addition of perioperative multi‐agent chemotherapy to the treatment strategy for locally advanced rectal cancer (LARC) may be a promising option. We conducted a phase II study to evaluate the safety and efficacy of capecitabine combined with oxaliplatin and irinotecan (XELOXIRI) as triplet neoadjuvant chemotherapy in patients with LARC. Methods Patients received neoadjuvant irinotecan and oxaliplatin and capecitabine and then underwent total mesorectal excision. The primary study endpoint was the pathological complete response (pCR) rate. Results Between June 2013 and December 2016, 55 patients were enrolled in the study. Forty‐two (77.8%) of 54 completed the study protocol. The pCR rate was 7.7% (95% CI 3.0% to 18.2%). The 3‐year local recurrence rate was 3.9%, the 3‐year disease‐free survival (DFS) rate was 77.3, and the 3‐year overall survival rate was 96.0%. Conclusion XELOXIRI neoadjuvant chemotherapy appears to be feasible and efficacious for patients with LARC. Although neoadjuvant XELOXIRI alone did not yield our expected pCR rate, the local recurrence rate, 3‐year DFS, and measures of safety met current standards.https://doi.org/10.1002/ags3.12600capecitabineirinotecanneoadjuvant chemotherapyoxaliplatinrectal cancer |
| spellingShingle | Chu Matsuda Toshihiro Kudo Yoshihiro Morimoto Yoshinori Kagawa Mitsuyoshi Tei Yoshihito Ide Norikatsu Miyoshi Hidekazu Takahashi Mamoru Uemura Ichiro Takemasa Taroh Satoh Tsunekazu Mizushima Kohei Murata Yuichiro Doki Hidetoshi Eguchi Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group (MSCSGO) A phase II study of neoadjuvant capecitabine, oxaliplatin, and irinotecan (XELOXIRI) in patients with locally advanced rectal cancer Annals of Gastroenterological Surgery capecitabine irinotecan neoadjuvant chemotherapy oxaliplatin rectal cancer |
| title | A phase II study of neoadjuvant capecitabine, oxaliplatin, and irinotecan (XELOXIRI) in patients with locally advanced rectal cancer |
| title_full | A phase II study of neoadjuvant capecitabine, oxaliplatin, and irinotecan (XELOXIRI) in patients with locally advanced rectal cancer |
| title_fullStr | A phase II study of neoadjuvant capecitabine, oxaliplatin, and irinotecan (XELOXIRI) in patients with locally advanced rectal cancer |
| title_full_unstemmed | A phase II study of neoadjuvant capecitabine, oxaliplatin, and irinotecan (XELOXIRI) in patients with locally advanced rectal cancer |
| title_short | A phase II study of neoadjuvant capecitabine, oxaliplatin, and irinotecan (XELOXIRI) in patients with locally advanced rectal cancer |
| title_sort | phase ii study of neoadjuvant capecitabine oxaliplatin and irinotecan xeloxiri in patients with locally advanced rectal cancer |
| topic | capecitabine irinotecan neoadjuvant chemotherapy oxaliplatin rectal cancer |
| url | https://doi.org/10.1002/ags3.12600 |
| work_keys_str_mv | AT chumatsuda aphaseiistudyofneoadjuvantcapecitabineoxaliplatinandirinotecanxeloxiriinpatientswithlocallyadvancedrectalcancer AT toshihirokudo aphaseiistudyofneoadjuvantcapecitabineoxaliplatinandirinotecanxeloxiriinpatientswithlocallyadvancedrectalcancer AT yoshihiromorimoto aphaseiistudyofneoadjuvantcapecitabineoxaliplatinandirinotecanxeloxiriinpatientswithlocallyadvancedrectalcancer AT yoshinorikagawa aphaseiistudyofneoadjuvantcapecitabineoxaliplatinandirinotecanxeloxiriinpatientswithlocallyadvancedrectalcancer AT mitsuyoshitei aphaseiistudyofneoadjuvantcapecitabineoxaliplatinandirinotecanxeloxiriinpatientswithlocallyadvancedrectalcancer AT yoshihitoide aphaseiistudyofneoadjuvantcapecitabineoxaliplatinandirinotecanxeloxiriinpatientswithlocallyadvancedrectalcancer AT norikatsumiyoshi aphaseiistudyofneoadjuvantcapecitabineoxaliplatinandirinotecanxeloxiriinpatientswithlocallyadvancedrectalcancer AT hidekazutakahashi aphaseiistudyofneoadjuvantcapecitabineoxaliplatinandirinotecanxeloxiriinpatientswithlocallyadvancedrectalcancer AT mamoruuemura aphaseiistudyofneoadjuvantcapecitabineoxaliplatinandirinotecanxeloxiriinpatientswithlocallyadvancedrectalcancer AT ichirotakemasa aphaseiistudyofneoadjuvantcapecitabineoxaliplatinandirinotecanxeloxiriinpatientswithlocallyadvancedrectalcancer AT tarohsatoh aphaseiistudyofneoadjuvantcapecitabineoxaliplatinandirinotecanxeloxiriinpatientswithlocallyadvancedrectalcancer AT tsunekazumizushima aphaseiistudyofneoadjuvantcapecitabineoxaliplatinandirinotecanxeloxiriinpatientswithlocallyadvancedrectalcancer AT koheimurata aphaseiistudyofneoadjuvantcapecitabineoxaliplatinandirinotecanxeloxiriinpatientswithlocallyadvancedrectalcancer AT yuichirodoki aphaseiistudyofneoadjuvantcapecitabineoxaliplatinandirinotecanxeloxiriinpatientswithlocallyadvancedrectalcancer AT hidetoshieguchi aphaseiistudyofneoadjuvantcapecitabineoxaliplatinandirinotecanxeloxiriinpatientswithlocallyadvancedrectalcancer AT multicenterclinicalstudygroupofosakacolorectalcancertreatmentgroupmscsgo aphaseiistudyofneoadjuvantcapecitabineoxaliplatinandirinotecanxeloxiriinpatientswithlocallyadvancedrectalcancer AT chumatsuda phaseiistudyofneoadjuvantcapecitabineoxaliplatinandirinotecanxeloxiriinpatientswithlocallyadvancedrectalcancer AT toshihirokudo phaseiistudyofneoadjuvantcapecitabineoxaliplatinandirinotecanxeloxiriinpatientswithlocallyadvancedrectalcancer AT yoshihiromorimoto phaseiistudyofneoadjuvantcapecitabineoxaliplatinandirinotecanxeloxiriinpatientswithlocallyadvancedrectalcancer AT yoshinorikagawa phaseiistudyofneoadjuvantcapecitabineoxaliplatinandirinotecanxeloxiriinpatientswithlocallyadvancedrectalcancer AT mitsuyoshitei phaseiistudyofneoadjuvantcapecitabineoxaliplatinandirinotecanxeloxiriinpatientswithlocallyadvancedrectalcancer AT yoshihitoide phaseiistudyofneoadjuvantcapecitabineoxaliplatinandirinotecanxeloxiriinpatientswithlocallyadvancedrectalcancer AT norikatsumiyoshi phaseiistudyofneoadjuvantcapecitabineoxaliplatinandirinotecanxeloxiriinpatientswithlocallyadvancedrectalcancer AT hidekazutakahashi phaseiistudyofneoadjuvantcapecitabineoxaliplatinandirinotecanxeloxiriinpatientswithlocallyadvancedrectalcancer AT mamoruuemura phaseiistudyofneoadjuvantcapecitabineoxaliplatinandirinotecanxeloxiriinpatientswithlocallyadvancedrectalcancer AT ichirotakemasa phaseiistudyofneoadjuvantcapecitabineoxaliplatinandirinotecanxeloxiriinpatientswithlocallyadvancedrectalcancer AT tarohsatoh phaseiistudyofneoadjuvantcapecitabineoxaliplatinandirinotecanxeloxiriinpatientswithlocallyadvancedrectalcancer AT tsunekazumizushima phaseiistudyofneoadjuvantcapecitabineoxaliplatinandirinotecanxeloxiriinpatientswithlocallyadvancedrectalcancer AT koheimurata phaseiistudyofneoadjuvantcapecitabineoxaliplatinandirinotecanxeloxiriinpatientswithlocallyadvancedrectalcancer AT yuichirodoki phaseiistudyofneoadjuvantcapecitabineoxaliplatinandirinotecanxeloxiriinpatientswithlocallyadvancedrectalcancer AT hidetoshieguchi phaseiistudyofneoadjuvantcapecitabineoxaliplatinandirinotecanxeloxiriinpatientswithlocallyadvancedrectalcancer AT multicenterclinicalstudygroupofosakacolorectalcancertreatmentgroupmscsgo phaseiistudyofneoadjuvantcapecitabineoxaliplatinandirinotecanxeloxiriinpatientswithlocallyadvancedrectalcancer |